APM
IMMU

Avidity Partners Management’s Immunomedics Inc IMMU Stock Holding History

Avidity Partners Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,911,300
Closed -$67.7M – 99
2020
Q2 		$67.7M Buy
1,911,300
+1,418,300
+288% +$41.5M 4.34% 5
2020
Q1 		$6.65M Buy
493,000
+353,000
+252% +$5.94M 0.92% 41
2019
Q4 		$2.96M Buy
+140,000
New +$2.47M 1.87% 25

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Avidity Partners Management's IMMU Position: Q3 2020 in Review

Avidity Partners Management sold out of Immunomedics Inc (IMMU) in Q3 2020, closing a stake of 1,911,300 shares — an estimated $67.7M sold.

Avidity Partners Management first reported a position in IMMU in Q4 2019 and held it in 3 quarters. The position peaked at $67.7M in Q2 2020. 408 funds tracked by Wall St. Rank hold IMMU as of Q3 2020.

  • Avidity Partners Management reported no remaining Immunomedics Inc position as of Q3 2020 after selling out during the quarter.
  • Avidity Partners Management sold 1,911,300 Immunomedics Inc shares in Q3 2020, an estimated $67.7M.
  • Avidity Partners Management first reported a position in Immunomedics Inc in Q4 2019 and held it in 3 quarters.
  • Avidity Partners Management's Immunomedics Inc position peaked at $67.7M in Q2 2020.
  • 408 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2020.

Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.